Enliven Therapeutics, Inc. ((ELVN)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enliven Therapeutics, Inc. is conducting a Phase 1a/1b study titled ‘A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia’. The study aims to assess the safety, tolerability, and determine the recommended dose of ELVN-001 for patients with chronic myeloid leukemia (CML), including those with T315I mutations, who have relapsed or are intolerant to tyrosine kinase inhibitors (TKIs). This study is significant as it explores a potential new treatment option for CML patients who have limited alternatives.
The intervention being tested is ELVN-001, an experimental drug administered orally once or twice daily. It is designed to achieve a deep molecular response in CML patients who do not respond well to existing TKIs.
The study follows a non-randomized, sequential intervention model with no masking. Its primary purpose is treatment, focusing on dose escalation and expansion to identify the optimal dosage for further clinical evaluation.
The study began on May 22, 2022, and its latest update was submitted on June 27, 2025. These dates are crucial as they mark the progress and ongoing nature of the study, which is still recruiting participants.
This update could influence Enliven Therapeutics’ stock performance positively if the results show promise, as it would position the company favorably in the competitive CML treatment market. Investors may view this as a potential growth opportunity, especially if ELVN-001 proves effective against T315I mutations, a challenging area for existing treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.